Cover Image
Market Research Report

Psoriasis - Pipeline Review, H2 2019

Published by Global Markets Direct Product code 232784
Published Content info 803 Pages
Delivery time: 1-2 business days
Price
Back to Top
Psoriasis - Pipeline Review, H2 2019
Published: November 25, 2019 Content info: 803 Pages
Description

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriasis - Pipeline Review, H2 2019, provides an overview of the Psoriasis (Immunology) pipeline landscape.

Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared up skin, itchiness, and burning sensation, swollen and stiff joints. Predisposing factors include heredity, side effects of certain medicines, stress, infections and environmental conditions. The condition may be controlled by topical or systemic medications and phototherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Psoriasis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Psoriasis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Psoriasis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 1, 25, 38, 62, 3, 126, 41 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 4 molecules, respectively.

Psoriasis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriasis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Psoriasis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Psoriasis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Psoriasis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Psoriasis (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Psoriasis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Psoriasis (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC11470IDB

Table of Contents

  • Introduction
  • Psoriasis - Overview
  • Psoriasis - Therapeutics Development
  • Psoriasis - Therapeutics Assessment
  • Psoriasis - Companies Involved in Therapeutics Development
  • Psoriasis - Drug Profiles
  • Psoriasis - Dormant Projects
  • Psoriasis - Discontinued Products
  • Psoriasis - Product Development Milestones
  • Appendix

List of Tables

  • Table 1: Number of Products under Development for Psoriasis, H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Table 7: Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Table 8: Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Table 9: Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
  • Table 10: Number of Products under Development by Companies, H2 2019 (Contd..8), H2 2019
  • Table 11: Number of Products under Development by Companies, H2 2019 (Contd..9), H2 2019
  • Table 12: Number of Products under Development by Companies, H2 2019 (Contd..10), H2 2019
  • Table 13: Number of Products under Development by Universities/Institutes, H2 2019
  • Table 14: Products under Development by Companies, H2 2019
  • Table 15: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 16: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Table 17: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Table 18: Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Table 19: Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Table 20: Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Table 21: Products under Development by Companies, H2 2019 (Contd..7), H2 2019
  • Table 22: Products under Development by Companies, H2 2019 (Contd..8), H2 2019
  • Table 23: Products under Development by Companies, H2 2019 (Contd..9), H2 2019
  • Table 24: Products under Development by Companies, H2 2019 (Contd..10), H2 2019
  • Table 25: Products under Development by Companies, H2 2019 (Contd..11), H2 2019
  • Table 26: Products under Development by Companies, H2 2019 (Contd..12), H2 2019
  • Table 27: Products under Development by Companies, H2 2019 (Contd..13), H2 2019
  • Table 28: Products under Development by Companies, H2 2019 (Contd..14), H2 2019
  • Table 29: Products under Development by Companies, H2 2019 (Contd..15), H2 2019
  • Table 30: Products under Development by Companies, H2 2019 (Contd..16), H2 2019
  • Table 31: Products under Development by Companies, H2 2019 (Contd..17), H2 2019
  • Table 32: Products under Development by Universities/Institutes, H2 2019
  • Table 33: Number of Products by Stage and Target, H2 2019
  • Table 34: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
  • Table 35: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
  • Table 36: Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
  • Table 37: Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
  • Table 38: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 39: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
  • Table 40: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
  • Table 41: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
  • Table 42: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
  • Table 43: Number of Products by Stage and Route of Administration, H2 2019
  • Table 44: Number of Products by Stage and Molecule Type, H2 2019
  • Table 45: Psoriasis - Pipeline by 3SBio Inc, H2 2019
  • Table 46: Psoriasis - Pipeline by AbbVie Inc, H2 2019
  • Table 47: Psoriasis - Pipeline by Abcentra LLC, H2 2019
  • Table 48: Psoriasis - Pipeline by AbClon Inc, H2 2019
  • Table 49: Psoriasis - Pipeline by Abeome Corp, H2 2019
  • Table 50: Psoriasis - Pipeline by AbGenomics International Inc, H2 2019
  • Table 51: Psoriasis - Pipeline by Abivax SA, H2 2019
  • Table 52: Psoriasis - Pipeline by Accuitis Pharmaceuticals Inc, H2 2019
  • Table 53: Psoriasis - Pipeline by Aclaris Therapeutics Inc, H2 2019
  • Table 54: Psoriasis - Pipeline by Actinobac Biomed Inc, H2 2019
  • Table 55: Psoriasis - Pipeline by ActoBio Therapeutics Inc, H2 2019
  • Table 56: Psoriasis - Pipeline by Aerie Pharmaceuticals Inc, H2 2019
  • Table 57: Psoriasis - Pipeline by Affibody AB, H2 2019
  • Table 58: Psoriasis - Pipeline by Affilogic SAS, H2 2019
  • Table 59: Psoriasis - Pipeline by Agragen LLC, H2 2019
  • Table 60: Psoriasis - Pipeline by Akeso Biopharma Inc, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Psoriasis, H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Figure 4: Number of Products by Top 10 Targets, H2 2019
  • Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
  • Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
  • Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
  • Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top